Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1073)	10/29/2001 9:49:22 AM
From: Arthur Radley	Respond to of 1475

Thanks! I was thinking about signing up to be a guinea pig.....we Texans are immune to toxics....just check the air we have to breath.

To: scaram(o)uche who wrote (1073)	10/29/2001 5:45:37 PM
From: Arthur Radley	Respond to of 1475

Taken from the Yahoo board....MEDI by: soldier30 Long-Term Sentiment: Strong Buy 10/29/01 02:19 pm Msg: 1258 of 1259 at the Salomon Smith Barney Healthcare conference today, MEDI formally unveiled additional clinical targets for MEDI-507 including psoriatic arthritis and T-cell lymphoma--at the breakout session, they also acknowledged that rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease were additional future targets at the breakout, someone asked what MEDI's 3 biggest drugs were in terms of market potential and MEDI-507 was mentioend by Jim Young, head of R+D as one of the 3-- with regard to psoriasis, Young said that there had been a number of patients with complete responses to MEDI-507 (his words were "the disease completely disappeared") and that the key issues going forward were trying to determine the interval of dosing and duration of treatment-- Overall, i was very pleased with his comments

To: scaram(o)uche who wrote (1073)	11/1/2001 5:28:17 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 1475

Appears that Biogen is moving back the date for Amevive to Q1-2003. This will allow MEDI/BTRN to cut the timeline for MEDI-507 submission and the headstart Biogen has currently. biz.yahoo.com Also it appears that MEDI will present at the CIBC conference in NYC on November 5th. This is normally a huge conference....so good exposure.

To: scaram(o)uche who wrote (1073)	11/6/2001 2:58:07 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 1475

FWIW, and I apologize if this has been posted before.......... MedImmune also initiated two Phase I clinical studies of Vitaxin, an anti-angiogenic antibody optimized by AME and licensed to MedImmune, for rheumatoid arthritis and colorectal cancer. Message 16615300 I remember MEDI talking about plans for Vitaxin in RA, but I don't remember their having initiated a trial. Again, apologies if this has been posted. Not feeling warm and fuzzy. Again, the MEDI spin on the phase II psoriasis results? It is not (no "IMO" is necessary) consistent with the actual results from the very small multi-dose i.v. trial. I still feel that a single ego is getting in the way of a rational test of low dose 507 for autoimmunity. I am sincerely concerned that the antibody will be used at concentrations where T cell depletion is pronounced, without ever having sufficiently tested lower doses.